On #RareDiseaseDay & every day, we leverage AI to repurpose drugs to treat #RareDiseases like TTR Amyloidosis, Phenylketonuria, Tardive Dyskinesia or Duchenne Muscular Dystrophy. ℹWe’re carrying out a Phase 2b clinical trial to treat Chorea in Huntington’s Disease. #CareForRare

It’s #RareDiseaseDay! Today and every day, awareness, support and research are essential. Most #RareDiseases are life threatening: there’s an urgent need to find new treatments. 💜💚💙 #LightUpForRare & #ShareYourColours #RareDiseaseDay2023 #LightUpForRare #ShareYourColours

14 days to go for #RareDiseaseDay! As researchers working to develop therapies for #RareDiseases, we’ll #LightUpForRare to raise #awareness and #support @rarediseaseday and 300 million people worldwide living with a rare disease. #ShareYourColours

Working with @caixabank to find investors in the European market and close a €32M #seriesb round to continue advancing in the development of drugs for the treatment of #rarediseases. Article by @expansioncom : bit.ly/3IbgYHX

SOM Biotech yesterday announced that it signed a licensing agreement with the University of Minnesota. You can find out more about this by following the link: lnkd.in/egbqis7H #drugdiscovery #licensing

We were happy to participate in the International Congress of Duchenne and Becker Spain. Thanks to @DPPSpain and @MarisolMontolio for the excellent organization of the event, and to the sponsors #catedraUBenfermedadesraras, @UniBarcelona #CongresoDPPS22 #duchenne #drugdiscovery

Yesterday @SOMBiotech participated in the poster session of the International Congress of Duchenne and Becker Spain (#CongresoDPPS22), organized by the @DPPSpain, and sponsored by #catedraUBenfermedadesraras of @UniBarcelona

@SOMBiotech will be presenting at the International #Duchenne Congress organized by @DPPSpain from the 13th to the 15th of May. The presentation will be dedicated to the repurposing strategies for this devastating muscle-wasting disease appearing in newborns. #CongresoDPPS22

We are happy to attend Outsourcing in Clinical Trials Europe 2022 on the 4th and 5th of May in Barcelona. It is a great opportunity to learn about the latest innovations and insights. arena-international.com/octe… #clinicaltrials #OCT

We are attending this year’s BIO-Europe Spring Virtual Conference. We look forward to hearing from industry experts and holding discussions with new partners. To schedule a meeting with SOM Biotech, click here: informaconnect.com/bioeurope… #BIOEurope22 #SOMBiotech

Yesterday our CEO, Raúl Insa participated, as a former winner of #EmprendedorXXI Awards, in the round table “Launching and scaling tech companies in Europe. A view from Spanish and Israeli founders” at Day One Innovation Summit Catalonia in the framework of #4YFN22.

Currently approved treatments for #Huntington’s disease are associated with a number of severe side effects. That’s why #RareDiseaseDay is important, as we aim to encourage education and further research into Rare Diseases, to address these unmet needs. rarediseaseday.org/

Phenylketonuria (PKU) occurs in an estimated 1 in 23,390 births globally. This #RareDiseaseDay, PKU sufferer, Michelle teamed up with @Eurordis to tell her story. Read here: rarediseaseday.org/heroes/pk…

#HuntingtonsDisease is a rare inherited neurodegenerative disorder of the central nervous system. Join us in supporting #RareDiseaseDay and raise awareness and generate change for those living with rare diseases, including Huntington’s. rarediseaseday.org/

Today is #RareDiseaseDay 2022! At SOM we recognize the importance of raising awareness and progressing scientific research in the field of #rarediseases. Join us and get involved today: rarediseaseday.org/#

We are soon approaching #RareDiseaseDay 2022! Did you know that over 300 million people from around the world have a rare disease? Learn more and get involved at: rarediseaseday.org/

We are excited to virtually attend this year’s BIO at J.P. Morgan and discuss our proprietary drug discovery platform SOMAIPRO. #JPM22 #healthcare #drugdiscovery bio.org/events/bio-partnerin…

Our Newsletter for Q4 of 2021 has been launched. Find it here lnkd.in/eJdpu2Pb You can subscribe to receive the latest updates on SOM Biotech via the newsletter, clicking the button "Subscribe" at the end of our webpage. We wish you a Merry Christmas and a Happy New Year!

We have signed a letter of intent with Megapharm regarding a potential distribution agreement for the commercialization of SOM3355 to treat chorea symptoms in Huntington’s disease in Israel and the Palestinian Authority. Read more here: sombiotech.com/som-biotech-s…

We are excited to present “SOM Biotech: Drug repurposing for Rare diseases” at the Open Innovation Madrid Norte Forum on science and technology today. For more information, click here: eventos.uam.es/74500/detail/…